Download Sanofi-Aventis Acquires Genzyme Corporation for $20 billion Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/1801555/
Sanofi-Aventis Acquires Genzyme Corporation for $20 billion
Description:
Sanofi-Aventis Acquires Genzyme Corporation for $20 billion - Deal Analysis from GlobalData
Summary
Following acquisition by Sanofi-Aventis for about $20 billion, Genzyme Corporation will become a new
platform in Sanofi-Aventis’s sustainable growth strategy and expand the company's presence in
biotechnology targeting rare diseases, renal-endocrinology, hematology-oncology, and the biosurgery
segment.
Genzyme will continue to operate out of its current headquarters in Massachusetts, and will be headed by
Sanofi-Aventis CEO Christopher Viehbacher.
Genzyme had earlier rejected several offers from Sanofi-Aventis last year, which included a deal worth $18.5
billion, or $69 per share. The two companies ultimately settled on a price of $74 per share.
Scope
- On April 8, 2011, Sanofi-aventis completed the acquisition of Genzyme for about $20 billion in total, or $74
per share plus extra payments of up to $14 per share. The extra payments would depend on the
achievement of commercial milestones of the leukemia drug Campath (alemtuzumab) in the multiple
sclerosis (MS) therapy area, where it will be sold as Lemtrada, for which Genzyme executives estimated sales
to reach $3.5 billion. They are also based on the production levels of Genzyme products Cerezyme
(imiglucerase) and Fabrazyme (agalsidase beta), which had commercial setbacks following manufacturing
issues in 2009.
Reasons to buy
- Several top selling products from Sanofi-Aventis such as Aprove, Lovenox, Multaq, Taxotere, and Plavix face
competition from generic versions, and this acquisition can ensure considerable expansion into rare
diseases, renal-endocrinology, hematology-oncology and the biosurgery segment.
- Genzyme's clinical research is focused on the areas of medicine where it markets commercial products,
namely rare inherited diseases, renal disease, orthopedics, oncology, transplantation, and immune diseases.
It also conducts research in cardiovascular disease, neurodegenerative diseases, and other areas with
unmet medical needs. The company has product candidates across various stages of development, from pre
-clinical studies to post-marketing studies.
Contents:
1
1
1.1 List of Tables
2 Summary
3 Deal Overview
4 Deal Rationale
5 Financials
6 Deal History
7 Companies Overview
7.1 Sanofi-Aventis
7.1.1 Overview
7.1.2 Chief Executive Officer (CEO)
7.1.3 Revenue (2010)
7.1.4 R&D Spend (2010)
7.1.5 Employee Strength
7.1.6 Geographic Presence
7.2 Genzyme
7.2.1 Overview
7.2.2 Chief Executive Officer (CEO)
7.2.3 Revenue (2010)
7.2.4 R&D Spend (2010)
7.2.5 Employee strength
7.2.6 Geographic Presence
8 Appendix
8.1 Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Expert Panel Validation
8.2 Contact Us
8.3 Disclaimer
1.1 List of Tables
Table 1: Genzyme Late Stage Drug Development Portfolio
Table 2: Comparison of Therapy Areas under Drug Development and Research
Ordering:
Order Online - http://www.researchandmarkets.com/reports/1801555/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Sanofi-Aventis Acquires Genzyme Corporation for $20 billion
Web Address:
http://www.researchandmarkets.com/reports/1801555/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Single User:
USD 500
Electronic (PDF) Site License:
USD 1000
Electronic (PDF) Enterprisewide:
USD 1500
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World